Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.

MK-0616 – administered orally – reduced LDL cholesterol in patients in two early clinical trials presented at the American Heart Association Scientific Sessions.

Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

Entasis is seeking a pathogen-specific approval for its antibiotic/beta lactamase inhibitor candidate rather than an indication specific the site of an infection. Achaogen’s earlier failure to do the same may have helped set a path.